Epothilones in the treatment of cancer
- 30 May 2006
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 15 (6), 691-702
- https://doi.org/10.1517/13543784.15.6.691
Abstract
Epothilones are cytotoxic macrolides with a similar mechanism of action to paclitaxel but with the potential advantage of activity in taxane-resistant settings in preclinical models. The epothilones ixabepilone, patupilone, BMS-310705, KOS-862 and ZK-EPO are in early clinical trials for cancer treatment. Phase I studies have shown that dose-limiting toxicities of epothilones are generally neurotoxicity and neutropoenia although initial studies with patupilone indicated that diarrhoea was dose limiting. Neuropathy induced by ixabepilone may be schedule dependent. Over 20 Phase II studies of epothilones in cancer treatment have been reported, and significant activity in taxane-sensitive tumour types (such as breast, lung and prostate cancers) has been noted. Response rates in taxane-refractory metastatic breast cancer are relatively modest, but ixabepilone and patupilone have shown promising efficacy in hormone-refractory metastatic prostate cancer and in taxane-refractory ovarian cancer.Keywords
This publication has 72 references indexed in Scilit:
- Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2005
- Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly DocetaxelJournal of Clinical Oncology, 2005
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal CancerClinical Cancer Research, 2005
- A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysCancer, 2005
- Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancerBreast Cancer Research and Treatment, 2005
- Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerEuropean Journal Of Cancer, 2004
- Drug resistance reversal—are we getting closer?European Journal Of Cancer, 2003
- Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five DaysJournal of Clinical Oncology, 2003
- New paradigms in the treatment of breast and colorectal cancer—an introductionEuropean Journal Of Cancer, 2002
- Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials groupEuropean Journal Of Cancer, 1994